Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Finite vs Continuous Nuc Therapy in CHB
NCT05793268Active, not recruiting
- Sponsor
- E-Da Hospital
- Start
- Dec 2022
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of entecavir, tenofovir disoproxil fumarate and tenofovir alafenamide in Chronic Hepatitis B (CHB) (2 arms), sponsored by E-Da Hospital. Primary endpoint: Number of Participants with seroclearance of HBsAg at 3 years. Started Dec 2022; status: active, not recruiting.
02
Drugs
entecavirtenofovir disoproxil fumaratetenofovir alafenamide
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT05793268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05793268.